Microbot Medical Inc
F:CY9D
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Microbot Medical Inc
F:CY9D
|
US |
|
J
|
J M Smucker Co
LSE:0L7F
|
US |
Microbot Medical Inc
Microbot Medical is a medical device company focused on robotic tools for minimally invasive procedures inside blood vessels. Its main product effort centers on endovascular robotics that help doctors guide devices through arteries and veins with more control and less manual handling. The company is not a hospital operator or drug maker; it sells specialized equipment for interventional medicine. The company makes money by developing and commercializing these robotic systems and related components for use by hospitals, clinics, and physicians who perform catheter-based procedures. Its customers are the medical professionals and healthcare facilities that need tools for vascular access, navigation, and treatment. In this industry, value comes from selling devices that fit into existing procedure workflows and support more precise delivery of care. What makes Microbot Medical different is its narrow focus on robotics for inside-the-body vascular procedures rather than broad surgical automation. That puts it in a small niche between traditional catheter tools and larger operating-room robotics companies. Investors should think of it as a specialty medtech company whose business depends on getting a highly specific robotic platform adopted in interventional medicine.
Microbot Medical is a medical device company focused on robotic tools for minimally invasive procedures inside blood vessels. Its main product effort centers on endovascular robotics that help doctors guide devices through arteries and veins with more control and less manual handling. The company is not a hospital operator or drug maker; it sells specialized equipment for interventional medicine.
The company makes money by developing and commercializing these robotic systems and related components for use by hospitals, clinics, and physicians who perform catheter-based procedures. Its customers are the medical professionals and healthcare facilities that need tools for vascular access, navigation, and treatment. In this industry, value comes from selling devices that fit into existing procedure workflows and support more precise delivery of care.
What makes Microbot Medical different is its narrow focus on robotics for inside-the-body vascular procedures rather than broad surgical automation. That puts it in a small niche between traditional catheter tools and larger operating-room robotics companies. Investors should think of it as a specialty medtech company whose business depends on getting a highly specific robotic platform adopted in interventional medicine.
Pipeline progress: Microbot said its Self-Cleaning Shunt and TipCAT programs are moving ahead, with animal and in vitro studies running in parallel and initial data expected around the hydrocephalus conference in Japan in late September.
Cash runway: Management said the company had a little over $13 million in cash, plus $400,000 in escrow, and believes that is enough to fund operations for 24 to 30 months.
Spending outlook: The company said its annual burn rate should be about $1 million per year, with lower G&A expected ahead as the company moves past some one-time public-company and financing costs.
FDA path: Management reiterated that it remains on track to submit for FDA approval in the later part of 2018 for the hydrocephalus shunt program, using a 510(k) or novel 510(k) pathway.
Partnerships and grants: The company said it is actively exploring collaborations, M&A, and other partnerships, and also highlighted non-dilutive Israeli government grants that have helped fund development.
Competitive position: Management described the Self-Cleaning Shunt as operating in a largely open field, with little direct competition and what it believes is a meaningful head start over others.
